Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2992
Jonathan T. Lei, Chen Huang, R. R. Srinivasan, S. Vasaikar, L. Dobrolecki, Alaina N. Lewis, Christina Sallas, S. Hilsenbeck, C. Osborne, M. Rimawi, M. Ellis, V. Petrosyan, Alexander B. Saltzman, A. Malovannaya, G. Wulf, D. Kraushaar, Tao Wang, G. Echeverria, Bing Zhang, M. Lewis
{"title":"Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance","authors":"Jonathan T. Lei, Chen Huang, R. R. Srinivasan, S. Vasaikar, L. Dobrolecki, Alaina N. Lewis, Christina Sallas, S. Hilsenbeck, C. Osborne, M. Rimawi, M. Ellis, V. Petrosyan, Alexander B. Saltzman, A. Malovannaya, G. Wulf, D. Kraushaar, Tao Wang, G. Echeverria, Bing Zhang, M. Lewis","doi":"10.1158/1538-7445.AM2021-2992","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2992","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44882064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-3145
Nathan P. McMahon, Allison Solanki, Jocelyn A. Jones, Lei G. Wang, K. Tichauer, K. Samkoe, Summer L. Gibbs
{"title":"Abstract 3145: TRIPODD: a novel fluorescence imaging platform for in situ quantification of drug distribution and therapeutic response","authors":"Nathan P. McMahon, Allison Solanki, Jocelyn A. Jones, Lei G. Wang, K. Tichauer, K. Samkoe, Summer L. Gibbs","doi":"10.1158/1538-7445.AM2021-3145","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3145","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44898617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2755
Kyung-Ho Pyo, H. K. Lee, H. Jo, Wongeun Lee, S. Heo, S. Lim, Dong Kwon Kim, Chun-Bong Synn, Y. Byeon, Young Seob Kim, B. Ahn, M. Hong, S. Lim, H. Kim, B. Cho
{"title":"Abstract 2755: Single-cell RNA sequencing reveals priming professional antigen-presenting macrophages and chemokine expressing T cells in tumor microenvironment by AXL inhibitor, SKI-G-801","authors":"Kyung-Ho Pyo, H. K. Lee, H. Jo, Wongeun Lee, S. Heo, S. Lim, Dong Kwon Kim, Chun-Bong Synn, Y. Byeon, Young Seob Kim, B. Ahn, M. Hong, S. Lim, H. Kim, B. Cho","doi":"10.1158/1538-7445.AM2021-2755","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2755","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44961716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2995
Gabriela Vazquez Rodriguez, Z. Ali, Anna Erkstam, J. Schueler, A. Fahlgren, Lasse D. Jensen
{"title":"Abstract 2995: Zebrafish tumor-derived xenografts established from breast cancer pdx models predict treatment outcome and dissemination risk with superior sensitivity and specificity","authors":"Gabriela Vazquez Rodriguez, Z. Ali, Anna Erkstam, J. Schueler, A. Fahlgren, Lasse D. Jensen","doi":"10.1158/1538-7445.AM2021-2995","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2995","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45028725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2936
J. Tien, Seema Chugh, Andrew Goodrum, Yun-Chien Cheng, Lisha Wang, R. Mannan, Xiaoming Wang, Vijaya L. Dommeti, Yuping Zhang, A. Xu, Fengyun Su, Xuhong Cao, Sunita Shankar, A. Chinnaiyan
{"title":"Abstract 2936: Ago2 induces Kras signaling and promotes tumor progression in mouse models of lung adenocarcinoma","authors":"J. Tien, Seema Chugh, Andrew Goodrum, Yun-Chien Cheng, Lisha Wang, R. Mannan, Xiaoming Wang, Vijaya L. Dommeti, Yuping Zhang, A. Xu, Fengyun Su, Xuhong Cao, Sunita Shankar, A. Chinnaiyan","doi":"10.1158/1538-7445.AM2021-2936","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2936","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45205911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2830
M. Tobi, F. Antaki, MaryAnn Rambus, E. Levi, H. Talwar, M. Lawson, B. McVicker
{"title":"Abstract 2830: Effect of tobacco and alcohol intake on the future development of liver metastasis","authors":"M. Tobi, F. Antaki, MaryAnn Rambus, E. Levi, H. Talwar, M. Lawson, B. McVicker","doi":"10.1158/1538-7445.AM2021-2830","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2830","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49062030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2771
Lakshmi Chandramohan, Q. Au, M. Nagy, E. Parnell, T. Peters
{"title":"Abstract 2771: Comprehensive analysis of immuno oncology markers in the tumor microenvironment of solid tumor samples using GeoMxTMdigital spatial profiler (DSP) and MultiOmyxTMhyperplexed immunofluorescence (IF)","authors":"Lakshmi Chandramohan, Q. Au, M. Nagy, E. Parnell, T. Peters","doi":"10.1158/1538-7445.AM2021-2771","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2771","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49252112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-3180
Yuankun Zhang, Qingxiao Song, Michael Lee, Haidong Tang, Kaniel Cassady, yang-xin fu, Dustin E. Schones, A. Riggs, Ru Feng, D. Zeng
{"title":"Abstract 3180: Blockade of PD-L1 interaction with CD80in transaugments anti-tumor immunity by increasing NOS2 in tumor-associated macrophages","authors":"Yuankun Zhang, Qingxiao Song, Michael Lee, Haidong Tang, Kaniel Cassady, yang-xin fu, Dustin E. Schones, A. Riggs, Ru Feng, D. Zeng","doi":"10.1158/1538-7445.AM2021-3180","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3180","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43146583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-3039
R. Lock, K. Evans, Narimanne El-Zein, E. Earley, S. Erickson, B. Teicher, Malcolm A. Smith
Introduction: While children with acute lymphoblastic leukemia (ALL) experience close to a 90% likelihood of cure, the outcome for certain high-risk pediatric ALL subtypes remains poor. Spleen Tyrosine Kinase (SYK), a cytosolic nonreceptor tyrosine kinase, is primarily expressed in the hematopoietic lineage and is essential for B-cell receptor signaling. It is associated with malignant transformation, cancer cell proliferation, and is a prominent tyrosine-phosphorylated protein in B-lineage pediatric ALL (Dolai et al, Cancer Res 76:2766-77, 2016). Fms Related Receptor Tyrosine Kinase 3 (FLT3) is a Class III receptor tyrosine kinase that regulates hematopoiesis. While uncommon in ALL, activating FLT3 mutations and internal tandem duplications are associated with poor outcome. TAK-659 is a dual SYK/FLT3 reversible inhibitor currently undergoing clinical trials against B-cell lymphoma, acute myeloid leukemia and solid tumors. Therefore, it was of interest for the Pediatric Preclinical Testing Consortium to test TAK-659 in vivo against its patient-derived xenograft (PDX) models of pediatric ALL. Methods: SYK and FLT3 mRNA expression in ALL PDXs was quantified by RNAseq (https://pedcbioportal.org) and 8 B-lineage pediatric ALL PDXs (3 B-cell precursor, BCP; 4 mixed-lineage leukemia-rearranged, MLLr; one Philadelphia Chromosome-like, Ph-like) were selected for testing. Engraftment was evaluated by enumerating the proportion of human CD45+ cells (%huCD45+) in the peripheral (PB) blood at weekly intervals. TAK-659 was tested at 60 mg/kg by oral gavage daily for 21 days. Events were defined as %huCD45+ ≥ 25%. At Day 28 post-treatment initiation or event (whichever occurred first), 4 mice/group were humanely killed to assess leukemia infiltration in the spleen and bone marrow (BM). Drug efficacy was assessed by event-free survival (EFS) of treated (T) and control (C) groups by T-C, T/C and stringent objective response measures (Houghton et al, Pediatr Blood Cancer 49:928-40, 2007). Results: The in vivo efficacy of TAK-659 was evaluated against B-lineage PDXs as FLT3 and SYK mRNA expression was higher in the PDXs from this lineage compared with PDXs from T-ALL. TAK-659 was well tolerated and significantly prolonged the time to event in 6/8 PDXs (T-C 0-25.5 days, T/C 1.0-2.2). Only one MLLr-ALL obtained an objective response (partial response) with all other models exhibiting progressive disease. The minimum mean %huCD45+ was significantly reduced in 5/8 PDXs in TAK-659 treated mice compared to control. Despite significant reductions in %huCD45+ in the PB for 5/8 PDXs, TAK-659 did not significantly reduce the spleen or BM infiltration of any PDXs. Conclusion: TAK-659 exhibited low to moderate single-agent in vivo activity against pediatric B-ALL PDXs representative of diverse disease subtypes. (Supported by NCI Grants CA199000 and CA199922) Citation Format: Richard B. Lock, Kathryn Evans, Narimanne El-Zein, Eric J. Earley, Stephen W. Erickson, Beverly A. Tei
虽然儿童急性淋巴细胞白血病(ALL)的治愈率接近90%,但某些高危儿童ALL亚型的预后仍然很差。脾酪氨酸激酶(SYK)是一种细胞质非受体酪氨酸激酶,主要在造血谱系中表达,对b细胞受体信号传导至关重要。它与恶性转化、癌细胞增殖有关,是b系儿童ALL中一个重要的酪氨酸磷酸化蛋白(Dolai等,cancer Res 76:2766-77, 2016)。Fms相关受体酪氨酸激酶3 (FLT3)是一种调节造血功能的III类受体酪氨酸激酶。虽然在ALL中不常见,但激活FLT3突变和内部串联重复与不良预后相关。TAK-659是一种双SYK/FLT3可逆抑制剂,目前正在进行治疗b细胞淋巴瘤、急性髓性白血病和实体瘤的临床试验。因此,儿科临床前试验联盟有兴趣在体内测试TAK-659对其患者来源的异种移植(PDX)儿童ALL模型的疗效。方法:通过RNAseq (https://pedcbioportal.org)和8个b系儿童ALL PDXs(3个b细胞前体,BCP;4混合谱系白血病-重排;选择一个费城染色体样(Ph-like)进行检测。通过每周计数外周血中人CD45+细胞的比例(%huCD45+)来评估移植情况。TAK-659以60 mg/kg的剂量,每天灌胃21天。事件定义为%huCD45+≥25%。在治疗开始或事件发生后第28天(以先发生者为准),每组4只小鼠被人杀,以评估白血病在脾脏和骨髓的浸润(BM)。通过T-C、T/C和严格的客观反应指标,以治疗组(T)和对照组(C)的无事件生存期(EFS)来评估药物疗效(Houghton等,儿科血癌49:928-40,2007)。结果:TAK-659对b系pdx的体内疗效进行了评估,该谱系的pdx中FLT3和SYK mRNA的表达高于T-ALL的pdx。TAK-659耐受性良好,可显著延长6/8例患者的事件发生时间(T-C 0-25.5天,T/C 1.0-2.2)。只有一种MLLr-ALL获得了客观反应(部分反应),所有其他模型均表现出疾病的进行性。与对照组相比,TAK-659处理小鼠中5/8 pdx的最小平均%huCD45+显著降低。尽管5/8个pdx的PB中%huCD45+显著降低,但TAK-659没有显著减少任何pdx的脾脏或BM浸润。结论:TAK-659对代表不同疾病亚型的儿童B-ALL pdx具有低至中等的单药体内活性。(由NCI基金CA199000和CA199922资助)引文格式:Richard B. Lock, Kathryn Evans, Narimanne El-Zein, Eric J. Earley, Stephen W. Erickson, Beverly A. Teicher, Malcolm A. SmithSYK/FLT3双抑制剂TAK-659在小儿急性淋巴细胞白血病异种移植模型中的临床前试验联合评估[摘要]。见:美国癌症研究协会2021年年会论文集;2021年4月10日至15日和5月17日至21日。费城(PA): AACR;癌症杂志,2021;81(13 -增刊):摘要nr 3039。
{"title":"Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia","authors":"R. Lock, K. Evans, Narimanne El-Zein, E. Earley, S. Erickson, B. Teicher, Malcolm A. Smith","doi":"10.1158/1538-7445.AM2021-3039","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3039","url":null,"abstract":"Introduction: While children with acute lymphoblastic leukemia (ALL) experience close to a 90% likelihood of cure, the outcome for certain high-risk pediatric ALL subtypes remains poor. Spleen Tyrosine Kinase (SYK), a cytosolic nonreceptor tyrosine kinase, is primarily expressed in the hematopoietic lineage and is essential for B-cell receptor signaling. It is associated with malignant transformation, cancer cell proliferation, and is a prominent tyrosine-phosphorylated protein in B-lineage pediatric ALL (Dolai et al, Cancer Res 76:2766-77, 2016). Fms Related Receptor Tyrosine Kinase 3 (FLT3) is a Class III receptor tyrosine kinase that regulates hematopoiesis. While uncommon in ALL, activating FLT3 mutations and internal tandem duplications are associated with poor outcome. TAK-659 is a dual SYK/FLT3 reversible inhibitor currently undergoing clinical trials against B-cell lymphoma, acute myeloid leukemia and solid tumors. Therefore, it was of interest for the Pediatric Preclinical Testing Consortium to test TAK-659 in vivo against its patient-derived xenograft (PDX) models of pediatric ALL. Methods: SYK and FLT3 mRNA expression in ALL PDXs was quantified by RNAseq (https://pedcbioportal.org) and 8 B-lineage pediatric ALL PDXs (3 B-cell precursor, BCP; 4 mixed-lineage leukemia-rearranged, MLLr; one Philadelphia Chromosome-like, Ph-like) were selected for testing. Engraftment was evaluated by enumerating the proportion of human CD45+ cells (%huCD45+) in the peripheral (PB) blood at weekly intervals. TAK-659 was tested at 60 mg/kg by oral gavage daily for 21 days. Events were defined as %huCD45+ ≥ 25%. At Day 28 post-treatment initiation or event (whichever occurred first), 4 mice/group were humanely killed to assess leukemia infiltration in the spleen and bone marrow (BM). Drug efficacy was assessed by event-free survival (EFS) of treated (T) and control (C) groups by T-C, T/C and stringent objective response measures (Houghton et al, Pediatr Blood Cancer 49:928-40, 2007). Results: The in vivo efficacy of TAK-659 was evaluated against B-lineage PDXs as FLT3 and SYK mRNA expression was higher in the PDXs from this lineage compared with PDXs from T-ALL. TAK-659 was well tolerated and significantly prolonged the time to event in 6/8 PDXs (T-C 0-25.5 days, T/C 1.0-2.2). Only one MLLr-ALL obtained an objective response (partial response) with all other models exhibiting progressive disease. The minimum mean %huCD45+ was significantly reduced in 5/8 PDXs in TAK-659 treated mice compared to control. Despite significant reductions in %huCD45+ in the PB for 5/8 PDXs, TAK-659 did not significantly reduce the spleen or BM infiltration of any PDXs. Conclusion: TAK-659 exhibited low to moderate single-agent in vivo activity against pediatric B-ALL PDXs representative of diverse disease subtypes. (Supported by NCI Grants CA199000 and CA199922) Citation Format: Richard B. Lock, Kathryn Evans, Narimanne El-Zein, Eric J. Earley, Stephen W. Erickson, Beverly A. Tei","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43207883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-3149
Beilei Liu
{"title":"Abstract 3149: Investigation of the potential therapeutic value of CAF-derived milk fat globule-EGF factor 8 protein (MFG-E8) in esophageal squamous cell carcinoma","authors":"Beilei Liu","doi":"10.1158/1538-7445.AM2021-3149","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3149","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41989657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}